Target

NTRK

Neurotrophic tyrosine receptor kinase

Also: NTRK1, NTRK2, NTRK3, TRKA, TRKB

14open trials
24trials in total
88publications
0researchers

Diseases

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Trial
Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion
31 Oct 2026· NA · NOT_YET_RECRUITING· CTGOV
Publication
NTRK1-Rearranged Cutaneous Non-Langerhans Cell Histiocytosis With Durable Response to TRK Inhibitor in a Patient With Primary Myelofibrosis.
28 Oct 2026· Journal of cutaneous pathology· PUBMED
Publication
A Case of Primary Intramedullary Infantile Fibrosarcoma With an RBPMS::NTRK3 Fusion and Response to Larotrectinib.
1 Oct 2026· Neuropathology and applied neurobiology· PUBMED
Publication
Uterine NTRK-Rearranged Spindle Cell Neoplasm With Unusual Morphology-A Case Report and Literature Review.
19 Sept 2026· International journal of surgical pathology· PUBMED
Publication
Primary NTRK-rearranged spindle cell sarcoma of the colon with ETV6-NTRK3 fusion.
17 Sept 2026· BMJ case reports· PUBMED
Publication
Gene Expression Profiling of URGCP and NTRK1-3/MAPK Pathway Genes in Soft Tissue Sarcomas.
17 Sept 2026· Journal of clinical practice and research· PUBMED
Publication
Poor Prognosis and High Recurrence in NTRK3 Fusion Cervical Sarcoma: A Series of 3 Cases and Literature Review.
16 Sept 2026· International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists· PUBMED
Publication
LMNA-NTRK1 fusion-positive MSI-high colorectal cancer responding to FOLFOX plus bevacizumab after immune checkpoint inhibitor failure: a case report.
12 Sept 2026· International cancer conference journal· PUBMED
Publication
Tumor-Agnostic and Histology-Tuned Targeted Therapies in Gastrointestinal Cancers: NTRK and RET Fusions and the Evolving Role of Molecular Basket Strategies.
4 Sept 2026· Journal of gastrointestinal cancer· PUBMED
Publication
Not all NTRK fusions in mesenchymal neoplasia are driver events: implications on classification and targeted therapy.
1 Sept 2026· The journal of pathology. Clinical research· PUBMED
Publication
Utility of RNA Sequencing and Immunohistochemistry for NTRK Fusion in Thyroid Carcinoma.
1 Sept 2026· Anticancer research· PUBMED
Publication
Acquired TPM3::NTRK1 fusion as a novel off-target resistance mechanism to selpercatinib in RET-positive lung adenocarcinoma: a case report.
28 Aug 2026· Frontiers in oncology· PUBMED
Publication
NTRK-positive collision tumor of the gastrointestinal tract: a rare entity case report.
26 Aug 2026· Annals of medicine and surgery (2012)· PUBMED
Publication
Perineuronal net degradation in aggressive glioblastomas with KANK1::NTRK2 fusions.
20 Aug 2026· Neuro-oncology advances· PUBMED
Trial
Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study
10 Aug 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Adult Sarcomas with NTRK Fusions: Clinicopathologic and Genomic Heterogeneity.
6 Aug 2026· Cancers· PUBMED
Publication
Real-World Evidence for Oncology Patients With Rare NTRK Gene Fusions: Final Results From the German Multicenter Patient Cohort Study REALTRK.
4 Aug 2026· JCO precision oncology· PUBMED
Publication
Targeting Wild-type NTRK in NTRK Fusion-Negative Lung Cancer Decreases Brain Metastases.
1 Aug 2026· Cancer research communications· PUBMED
Publication
A High-Grade CD34-Positive Spindle Cell Sarcoma of the Palm Revealing an Unexpected TPM3::NTRK1 Fusion: A Diagnostic Pitfall With Major Therapeutic Implications.
29 Jul 2026· Applied immunohistochemistry & molecular morphology : AIMM· PUBMED
Publication
NTRK fusion in metastatic castration-resistant prostate cancer treated with entrectinib: a case report.
17 Jul 2026· Journal of medical case reports· PUBMED
Publication
Regulatory Perspectives in Precision Oncology: Challenges and Opportunities for Tyrosine Receptor Kinase (NTRK) Inhibitors in Non-small Cell Lung Cancer (NSCLC).
13 Jul 2026· Cureus· PUBMED
Publication
Fingolimod Acutely Facilitates the Activation of TRKB in a BDNF-dependent Manner.
8 Jul 2026· Cellular and molecular neurobiology· PUBMED
Publication
Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential tyrosine receptor kinase inhibitors.
7 Jul 2026· Clinical journal of gastroenterology· PUBMED
Publication
Case report: Secretory carcinoma of the breast with ETV6-NTRK3 fusion: clinicopathological features and molecular confirmation by FISH in two cases.
2 Jul 2026· Frontiers in oncology· PUBMED
Publication
Cancer of Unknown Primary Most Suggestive of Colorectal Origin With Microsatellite Instability-high Status and High Tumor Mutation Burden Including NTRK Fusion.
1 Jul 2026· Cancer diagnosis & prognosis· PUBMED
Publication
Driver vs. passenger: Primary resistance to larotrectinib in synovial sarcoma harboring concurrent SS18 rearrangement and PDE3A-NTRK2 fusion.
30 Jun 2026· Tumori· PUBMED
Publication
Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer.
28 Jun 2026· Lung cancer (Amsterdam, Netherlands)· PUBMED
Publication
Correction: Garrido et al. NGF/TRKA Decrease miR-145-5p Levels in Epithelial Ovarian Cancer Cells. Int. J. Mol. Sci. 2020, 21, 7657.
24 Jun 2026· International journal of molecular sciences· PUBMED
Publication
Navigating NTRK in Non-small Cell Lung Cancer (NSCLC): A Patient Perspective.
23 Jun 2026· Cureus· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error